Tao Fu Founder of Attovia Backed byLogos CapitalGraham Walmsley LinkedIn SourcesAttovia Therapeutics Announces First Participant Dosed in First-in-Human Phase 1 Study of ATTO-1310, its Novel Half-life Extended Anti-IL-31 ATTOBODY for the Treatment of Chronic Pruritus — 2025-01 Browse all founders · Browse investors
